Treatment of Recurrent Herpes Simplex Labialis with Oral Acyclovir

In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97% of the patients, treatment start...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1990-02, Vol.161 (2), p.185-190
Main Authors: Spruance, Spotswood L., Stewart, Jeffery C. B., Rowe, Nathaniel H., McKeough, Mark B., Wenerstrom, Gay, Freeman, Donna J.
Format: Article
Language:English
Subjects:
Acyclovir - administration & dosage
Acyclovir - therapeutic use
Administration, Oral
Adult
Aged
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antivirals
Biological and medical sciences
Double-Blind Method
Erythema
Female
Genital herpes
Healing
Herpes labialis
Herpes Labialis - drug therapy
Herpes simplex
Humans
Infections
Lesions
Major Articles
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Placebos
Prospective Studies
Randomized Controlled Trials as Topic
Recurrence
Self Administration
Simplexvirus - drug effects
Simplexvirus - isolation & purification
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97% of the patients, treatment started within 1 h of the first sign or symptom of a recurrence. The frequency of positive lesion virus cultures was significantly lower among acyclovir-treated subjects (29/114,25%) than among placebo-treated subjects (29/60,48%; P = .004). Drug treatment did not affect the development of lesions, measured by the frequency of macular and papular (aborted) lesions and mean maximum lesion size. However, acyclovir hastened lesion resolution among the patients who could start treatment in the prodrome or erythema lesion stage. For this group, the mean duration of pain was reduced by 36% (P = .02)and the mean healing time to loss of crust by 27% (P = .03). Thus, oral acyclovir alleviated some of the clinical manifestations of herpes simplex labialis.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/161.2.185